Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients.
Recombinant human erythropoietin (rHuEPO) has been reported to induce hypertension. We investigated the effect of a single injection of rHuEPO on blood pressure in patients receiving hemodialysis (HD) and in patients with predialysis chronic renal failure (CRF). Forty-one patients receiving HD and 36 patients with predialysis CRF received an intravenous injection of rHuEPO, and blood pressure and plasma endothelin-1 were measured before and 30 min after the injection. Mean blood pressure was increased significantly in HD patients, but not in CRF patients (HD: 103+/-5 to 105+/-6 mmHg, p<0.05; CRF: 103+/-4 to 103+/-6, NS). The percentage of patients with increased mean blood pressure of more than 10 mmHg after rHuEPO injection was significantly larger in the HD than in the CRF group (27.0% vs. 5.5%, p<0.01). A positive correlation was found between changes in endothelin-1 level and mean blood pressure in the HD (r=0.43, p<0.01) but not in predialysis chronic renal failure. In conclusion, a single injection of rHuEPO increased blood pressure with a positive correlation with endothelin-1 release in hemodialysis patients, but not in predialysis chronic renal failure patients.
Miyashita
Kazuhisa
K
Division of Nephrology, the Japanese Red Cross Medical Center, Tokyo, Japan.
Tojo
Akihiro
A
Kimura
Kenjiro
K
Goto
Atsuo
A
Omata
Masao
M
Nishiyama
Keisuke
K
Fujita
Toshiro
T
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects*; D019332:Endothelin-1 / Q000378:metabolism; D004921:Erythropoietin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis
D019332:Endothelin-1; D011994:Recombinant Proteins; D004921:Erythropoietin